Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C21H34F2O5 |
| Molecular Weight | 404.4885 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC[C@H](C)CC(F)(F)[C@@]1(O)CC[C@H]2[C@@H](CC(=O)[C@@H]2CCCCCCC(O)=O)O1
InChI
InChIKey=SDDSJMXGJNWMJY-BRHAQHMBSA-N
InChI=1S/C21H34F2O5/c1-3-14(2)13-20(22,23)21(27)11-10-16-15(17(24)12-18(16)28-21)8-6-4-5-7-9-19(25)26/h14-16,18,27H,3-13H2,1-2H3,(H,25,26)/t14-,15+,16+,18+,21+/m0/s1
| Molecular Formula | C21H34F2O5 |
| Molecular Weight | 404.4885 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Cobristone is a locally acting chloride channel activator that works to stimulate and protect the mucosal barrier function. Cobristone is being developed by the Sucampo Pharmaceuticals, Inc. for the prevention of oral mucositis and for the treatment of non-erosive reflux disease (NERD), a major subtype of gastroesophageal reflux disease. The development of the drug was terminated after phase 2 clinical trials failed to meet its primary endpoints.
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:06:20 GMT 2025
by
admin
on
Mon Mar 31 18:06:20 GMT 2025
|
| Record UNII |
IL870Q3Z8I
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
158302
Created by
admin on Mon Mar 31 18:06:20 GMT 2025 , Edited by admin on Mon Mar 31 18:06:20 GMT 2025
|
||
|
NCI_THESAURUS |
C78276
Created by
admin on Mon Mar 31 18:06:20 GMT 2025 , Edited by admin on Mon Mar 31 18:06:20 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SS-121
Created by
admin on Mon Mar 31 18:06:20 GMT 2025 , Edited by admin on Mon Mar 31 18:06:20 GMT 2025
|
PRIMARY | |||
|
IL870Q3Z8I
Created by
admin on Mon Mar 31 18:06:20 GMT 2025 , Edited by admin on Mon Mar 31 18:06:20 GMT 2025
|
PRIMARY | |||
|
8865
Created by
admin on Mon Mar 31 18:06:20 GMT 2025 , Edited by admin on Mon Mar 31 18:06:20 GMT 2025
|
PRIMARY | |||
|
16757521
Created by
admin on Mon Mar 31 18:06:20 GMT 2025 , Edited by admin on Mon Mar 31 18:06:20 GMT 2025
|
PRIMARY | |||
|
100000178230
Created by
admin on Mon Mar 31 18:06:20 GMT 2025 , Edited by admin on Mon Mar 31 18:06:20 GMT 2025
|
PRIMARY | |||
|
333963-42-1
Created by
admin on Mon Mar 31 18:06:20 GMT 2025 , Edited by admin on Mon Mar 31 18:06:20 GMT 2025
|
PRIMARY | |||
|
C78117
Created by
admin on Mon Mar 31 18:06:20 GMT 2025 , Edited by admin on Mon Mar 31 18:06:20 GMT 2025
|
PRIMARY | |||
|
DB05514
Created by
admin on Mon Mar 31 18:06:20 GMT 2025 , Edited by admin on Mon Mar 31 18:06:20 GMT 2025
|
PRIMARY | |||
|
CHEMBL2103799
Created by
admin on Mon Mar 31 18:06:20 GMT 2025 , Edited by admin on Mon Mar 31 18:06:20 GMT 2025
|
PRIMARY | |||
|
DTXSID80187025
Created by
admin on Mon Mar 31 18:06:20 GMT 2025 , Edited by admin on Mon Mar 31 18:06:20 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> AGONIST |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
